1. Introduction {#sec1-jcm-09-02439}
===============

Knee osteoarthritis (OA) is a common degenerative osteoarticular disease, associating pain, stiffness, and loss of mobility. It affects 2% to 10% of men and 1.6% to 15% of women over age 40 depending on geographical areas and definitions of pathology \[[@B1-jcm-09-02439]\]. According to a US study, 45% of adults over age 45 will have knee OA before the age of 85 \[[@B2-jcm-09-02439]\]. OA has important consequences for quality of life, disability and mobility \[[@B1-jcm-09-02439]\] and is associated with an increase in mortality \[[@B3-jcm-09-02439]\]. It is a heterogeneous disorder characterized by various etiological factors, pathophysiological pathways, clinical phenotypes and prognosis \[[@B4-jcm-09-02439]\]. Indeed, more than half of patients with radiographic OA are not symptomatic; for 50% to 70%, disease will not worsen radiographically in 2 years; for 27%, disease will progress slowly or moderately; and for 2%, disease will progress rapidly, known as rapidly destructive OA of the knee \[[@B5-jcm-09-02439]\].

We lack long-term effective pharmacological treatment for OA, especially for frail patients, but nonpharmacological treatments (e.g., physical therapy, surgery) have been found effective \[[@B6-jcm-09-02439],[@B7-jcm-09-02439],[@B8-jcm-09-02439]\]. The use of surgery is frequent: the 2010 prevalence of knee replacement in the total US population was 1.52%, with 4.7 million individuals undergoing total knee replacement \[[@B9-jcm-09-02439]\]. In France in 2011, 86,000 knee replacements were performed, increasing by more than 33.0% between 2008 and 2013 \[[@B10-jcm-09-02439]\].

In end-stage knee OA, total knee arthroplasty (TKA) is an effective intervention to reduce pain and improve function for most patients. However, after TKA, some patients still experience pain, loss of function, deficient muscle strength or reduced walking speed.

Outcomes of patients with knee OA undergoing or after TKA are evaluated with many different instruments used both in clinical practice and in research. The Outcome Measures in Rheumatology Clinical Trials (OMERACT) group defined a core set of outcome dimensions for clinical studies in knee OA at its medical stage: pain, physical function (the performance of daily activities), and patient global assessment \[[@B11-jcm-09-02439],[@B12-jcm-09-02439]\]. In the same way, the International Classification of Functioning, Disability and Health (ICF) defined a core set of outcome dimensions: impairments of body functions and structures, activity limitations and participation restriction, and environmental factors \[[@B13-jcm-09-02439]\]. These comply with the recommendations of several guidelines for outcome measurement in OA trials (European League Against Rheumatism \[[@B14-jcm-09-02439]\], Osteoarthritis Research Society International \[[@B15-jcm-09-02439]\], US Food and Drug Administration \[[@B11-jcm-09-02439]\], and Slow-acting Drugs in Osteoarthritis \[[@B16-jcm-09-02439]\]). However, these guidelines differ in their recommendations for the use of specific instruments \[[@B14-jcm-09-02439],[@B15-jcm-09-02439]\] or simply lack any recommendations in this regard for knee OA undergoing or after TKA.

Many instruments, such as patient-reported outcome measures (PROMs) and physical tests, are available to assess the outcome dimensions of the OMERACT or ICF. However, which instruments are the most appropriate is unclear \[[@B17-jcm-09-02439]\]. In fields like satisfaction after TKA, we lack an objective assessment tool to evaluate the impact of TKA and to better understand the heterogeneity between a patient's post-surgery status \[[@B18-jcm-09-02439]\]. Instrument selection should depend on the instrument's psychometric qualities and on practical considerations (e.g., time to complete, ease of scoring or use, mode of administration and distribution, meaning its validity by use, whatever its metrological properties). Psychometric qualities refer mainly to the validity and reliability of the measuring tool \[[@B19-jcm-09-02439]\]. Validity meaning *"the extent to which an instrument measures what it is intended to measure"* and reliability the fact that the instrument is free of error \[[@B19-jcm-09-02439]\].

Several reviews of OA tools at the medical stage have been published, and a special issue on outcome measurements was published by *Arthritis Care & Research* \[[@B11-jcm-09-02439],[@B20-jcm-09-02439],[@B21-jcm-09-02439],[@B22-jcm-09-02439]\]. Two separate studies \[[@B23-jcm-09-02439],[@B24-jcm-09-02439]\] concluded that the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Oxford Knee Score (OKS) and the Medical Outcomes Study Short-Form 36 (SF-36) could be recommended as primary measures in treatment studies knowing that certain key areas such as reproducibility, responsiveness to clinical change, and minimal important change needed more rigorous evaluation to make stronger recommendations. However, none of these reviews focused on physical tests. In addition, an update 10 years later seems necessary in order to allow a complete overview of available instruments for patients with knee OA undergoing or after TKA. To assess the selected instruments, data on the descriptive and psychometric qualities of each instrument will be collected and rated by using the same checklist \[[@B21-jcm-09-02439],[@B22-jcm-09-02439]\].

The objective of this study was to give an overview of a core set of PROMs as well as physical tests used for clinical trials of individuals with knee OA undergoing TKA. This review will facilitate the choice of the most appropriate measurement instruments (PROMs and physical tests) for studies and clinical practice of patients with knee OA who are undergoing TKA.

2. Experimental Section {#sec2-jcm-09-02439}
=======================

The review and analysis were conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) \[[@B25-jcm-09-02439]\]. The systematic review protocol was registered in PROSPERO (CRD42020161878). Information regarding study selection, search strategy, inclusion and exclusion criteria, risk of bias and quality of evidence, data extraction, and psychometric qualities are shown in detail in the [Supplementary Materials](#app1-jcm-09-02439){ref-type="app"}.

2.1. Study Selection {#sec2dot1-jcm-09-02439}
--------------------

### 2.1.1. Search Strategy {#sec2dot1dot1-jcm-09-02439}

PubMed, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials and CINAHL databases were systematically searched for articles published from 2014 through December 2019. The broad computerized search strategy was built on key words for patients with OA of the knee undergoing TKA; search strategy for outcome assessment; and search strategy for control trial. Search terms are listed in Research Algorithm S1. Selection of articles was based on their title and abstract and was decided by two independent reviewers (VR and AV). Their inclusion was then decided after reading the full article by the same two independent reviewers. The full article was read by two other independent reviewers (FC and EC) in case of doubt or concern and if necessary, a third reviewer (SB) resolved disagreements.

Regarding clinimetric studies, a search following the same process and hierarchy was made using PubMed database. In addition, references of the retrieved articles were screened for relevant articles.

### 2.1.2. Inclusion and Exclusion Criteria {#sec2dot1dot2-jcm-09-02439}

Inclusion criteria were as follows: (1) Study design: all randomized controlled trials (RCTs) or clinical controlled trials (CCTs); (2) Patients: individuals with OA of the knee undergoing TKA; (3) Intervention: articles focused on unilateral and primary TKA (not total hip arthroplasty) because those patients were considered different patient populations; (4) Outcomes: data measured before and after TKA. Given the large number of articles published on this topic and considering that a certain number of outcomes have been used only recently (last 5 years), we included only articles published since 2014 (≤5 years); (5) Instruments: all outcomes (PROMs and physical tests) used as primary or secondary criteria. Finally, inclusion criteria at the level of clinimetric studies were as follows: article's main focus was the psychometric evaluation of the instrument (since no checklist to rate psychometric evaluations based on item response theory \[IRT\] is currently available, only psychometric evaluations involving usual test theory were included and evaluations based on IRT were excluded); data for patients with knee OA undergoing TKA were published independently in case of mixed populations (e.g., patients with OA undergoing total hip arthroplasty and patients with OA undergoing TKA); and results had been published in English as a full report.

2.2. Quality Assessment and Data Extraction {#sec2dot2-jcm-09-02439}
-------------------------------------------

The Physiotherapy Evidence Database (PEDro) scale \[[@B26-jcm-09-02439]\] was used to assess risk of bias within studies. At the level of clinimetric studies, to facilitate comparisons with other studies from 10 years ago \[[@B7-jcm-09-02439],[@B27-jcm-09-02439]\], fundamentally the same checklist of specific criteria for quality assessment of instruments was used ([Table S1](#app1-jcm-09-02439){ref-type="app"} for self-assessment tools and [Table S2](#app1-jcm-09-02439){ref-type="app"} for physical tests). This checklist was initially developed by Bot et al. \[[@B28-jcm-09-02439]\] based on the work by Lohr et al. \[[@B29-jcm-09-02439]\], the Scientific Advisory Committee of the Medical Outcomes Trust guidelines and the checklist developed by Bombardier and Tugwell \[[@B30-jcm-09-02439]\]. All qualities were rated as positive, doubtful, or negative. If no or insufficient information was available, no rating was given. Two reviewers (VR and AV) independently assessed the psychometric qualities of each instrument. Disagreements between reviewers were resolved by discussion. The highest rating was assigned when ≥2 studies were found on the same psychometric qualities of the same instrument involving the same population.

2.3. Characteristics of the Instruments {#sec2dot3-jcm-09-02439}
---------------------------------------

The descriptive data recovered provide information about the target population, domain assessed, format of the instruments and mandatory equipment for physical tests ([Table A1](#jcm-09-02439-t0A1){ref-type="table"}).

2.4. Psychometric Qualities {#sec2dot4-jcm-09-02439}
---------------------------

Psychometric qualities (validity, reproducibility, responsiveness, and interpretability) were assessed for each instrument in this specific population, namely knee OA, and more precisely TKA according to the COnsensus-based Standards for the selection of health status Measurement Instruments (COSMIN) recommendations \[[@B31-jcm-09-02439]\]. See [Supplementary Materials](#app1-jcm-09-02439){ref-type="app"} for more detailed information ([Table S1](#app1-jcm-09-02439){ref-type="app"} for self-assessment tools and [Table S2](#app1-jcm-09-02439){ref-type="app"} for physical tests).

2.5. Overall Quality {#sec2dot5-jcm-09-02439}
--------------------

As Bot et al. described \[[@B28-jcm-09-02439],[@B32-jcm-09-02439]\], overall score of the instruments was obtained by adding the number of positive ratings for each psychometric quality ([Table S1](#app1-jcm-09-02439){ref-type="app"} for self-assessment tools and [Table S2](#app1-jcm-09-02439){ref-type="app"} for physical tests).

2.6. Statistical Analysis {#sec2dot6-jcm-09-02439}
-------------------------

Except the calculation of the agreement kappa coefficient between two reviewers, statistical analyzes were exclusively descriptive and involved use of Microsoft Office Excel 2019 (Microsoft Corp., Redmond, WA, USA). To assess the concordance between the two reviewers proofreading, we calculate a kappa coefficient using Stata v13 (StataCorp, College Station, TX, USA), considering a categorical criterion, and the number of modalities of the variable studied.

3. Results {#sec3-jcm-09-02439}
==========

3.1. Study Selection {#sec3dot1-jcm-09-02439}
--------------------

A flow chart detailing the study selection process is shown in [Figure 1](#jcm-09-02439-f001){ref-type="fig"}. The initial searches returned a total of 2339 articles; 313 were duplicates. Titles and abstracts of the retrieved articles were assessed for suitability, leading to the retrieval of 105 full texts. Of these, 85 did not fulfill the inclusion criteria and reports for the remaining 20 studies were analyzed. The kappa statistic between two reviewers (VR and AV) was 0.74, which indicated good agreement \[[@B33-jcm-09-02439]\].

3.2. Study Characteristics {#sec3dot2-jcm-09-02439}
--------------------------

The included studies involved 1997 participants (1005 interventions and 992 controls). For 12 (60%) studies, the design was randomized controlled trial (RCTs). A summary of the included trials is shown in [Table 1](#jcm-09-02439-t001){ref-type="table"}.

3.3. Description of Outcomes {#sec3dot3-jcm-09-02439}
----------------------------

All included outcomes (*n =* 25) are presented in [Table 2](#jcm-09-02439-t002){ref-type="table"}. Half were questionnaires (*n =* 13, 52%) developed to assess pain (*n =* 8, 61%) and/or physical function (*n =* 6, 46%) in separate (sub)scales. These questionnaires could be divided into 3 categories: those assessing a specific condition (knee OA; *n =* 5, 38%), a patient specificity such as anxiety or depression (*n =* 4, 31%) and generic outcomes (*n =* 4, 31%) ([Table 3](#jcm-09-02439-t003){ref-type="table"}). Other outcomes were physical tests (*n =* 12, 48%) mostly developed to assess functional mobility (*n =* 6, 50%). We could distinguish analytical tests (*n =* 5, 42%) and performance-based tests (*n =* 7, 58%) such as walking tests (*n =* 4, 33%), sit-to-stand tests (*n =* 2, 17%) and stair climbing tests (*n =* 1, 8%) ([Table 3](#jcm-09-02439-t003){ref-type="table"}). Among the 25 outcomes, 13 (52%) were used as a primary outcome in RCTs and 21 (84%) as a secondary outcome (including 9 \[36%\] both primary and secondary outcomes) ([Table 2](#jcm-09-02439-t002){ref-type="table"}).

3.4. Risk of Bias Within Studies {#sec3dot4-jcm-09-02439}
--------------------------------

Eleven trials were considered high quality (PEDro score \>5/10), with a mean score of 5.9/10 across all trials ([Table 1](#jcm-09-02439-t001){ref-type="table"} and [Table A2](#jcm-09-02439-t0A2){ref-type="table"}). The total PEDro scores were 8 for 1 trial \[[@B53-jcm-09-02439]\], 7 for 8 trials \[[@B1-jcm-09-02439],[@B23-jcm-09-02439],[@B44-jcm-09-02439],[@B49-jcm-09-02439],[@B58-jcm-09-02439],[@B59-jcm-09-02439],[@B61-jcm-09-02439],[@B74-jcm-09-02439]\], 6 for 2 trials \[[@B45-jcm-09-02439],[@B46-jcm-09-02439]\], 5 for 6 trials \[[@B11-jcm-09-02439],[@B20-jcm-09-02439],[@B25-jcm-09-02439],[@B50-jcm-09-02439],[@B83-jcm-09-02439],[@B84-jcm-09-02439]\] and 4 for 3 trials \[[@B41-jcm-09-02439],[@B85-jcm-09-02439],[@B86-jcm-09-02439]\]. The items of the PEDro scale the most frequently found were eligibility criteria, outcome obtained in more than 85% of participants, the use of similar groups at baseline, measurements of variability for at least one key outcome, and between-group comparisons, which were evident in almost all reports. None of the trials reported blinding of participants or therapists nor assessors, which is expected, given that these items are the most difficult to adhere to in trials of non-pharmacological interventions involving exercise. Nineteen trials reported an intention-to-treat analysis, 9 used allocation concealment and 10 used random allocation.

3.5. Psychometric Qualities of Tools {#sec3dot5-jcm-09-02439}
------------------------------------

### 3.5.1. Content Validity {#sec3dot5dot1-jcm-09-02439}

Content validity was assessed for 9 (69%) of the 13 tools ([Figure 2](#jcm-09-02439-f002){ref-type="fig"} and [Table A4](#jcm-09-02439-t0A4){ref-type="table"}). The Knee Injury and Osteoarthritis Outcome Score (KOOS) \[[@B54-jcm-09-02439]\], OKS \[[@B30-jcm-09-02439],[@B42-jcm-09-02439]\], State-Trait Anxiety Index (STAI) \[[@B72-jcm-09-02439]\], Geriatric Depression Scale (GDS) \[[@B73-jcm-09-02439]\] and Hospital Anxiety and Depression Scale (HADS) \[[@B10-jcm-09-02439],[@B17-jcm-09-02439],[@B52-jcm-09-02439],[@B82-jcm-09-02439],[@B87-jcm-09-02439]\] had positive ratings based on several studies. The WOMAC \[[@B8-jcm-09-02439],[@B18-jcm-09-02439],[@B34-jcm-09-02439],[@B63-jcm-09-02439],[@B79-jcm-09-02439]\], New Knee Society Score (KSS) \[[@B29-jcm-09-02439],[@B70-jcm-09-02439]\], SF-36 \[[@B7-jcm-09-02439],[@B8-jcm-09-02439],[@B27-jcm-09-02439],[@B34-jcm-09-02439],[@B75-jcm-09-02439],[@B88-jcm-09-02439]\], SF-12 \[[@B7-jcm-09-02439],[@B28-jcm-09-02439],[@B34-jcm-09-02439],[@B38-jcm-09-02439],[@B88-jcm-09-02439]\] and Pain Catastrophizing Score (PCS) \[[@B82-jcm-09-02439]\] had indeterminate (doubtful) ratings regarding the lack of clear and complete documentation of the item selection process.

### 3.5.2. Internal Consistency {#sec3dot5dot2-jcm-09-02439}

Both factor analysis (or a similar method, e.g., principal component analysis) and calculation of Cronbach *α* were performed for only 6 (46%) tools (or particular subscales only, e.g., pain), namely, WOMAC \[[@B8-jcm-09-02439],[@B18-jcm-09-02439],[@B63-jcm-09-02439],[@B79-jcm-09-02439],[@B89-jcm-09-02439]\], KOOS \[[@B55-jcm-09-02439]\], KSS \[[@B29-jcm-09-02439],[@B70-jcm-09-02439]\], OKS \[[@B30-jcm-09-02439],[@B42-jcm-09-02439]\], STAI \[[@B72-jcm-09-02439]\] and GDS \[[@B73-jcm-09-02439]\]. For most of the remaining studies, the Cronbach α was determined, and studies involving the SF-36 \[[@B34-jcm-09-02439],[@B35-jcm-09-02439]\], SF-12 \[[@B7-jcm-09-02439],[@B28-jcm-09-02439],[@B38-jcm-09-02439],[@B88-jcm-09-02439]\] and PCS \[[@B82-jcm-09-02439]\] showed values of ≥0.7 for all subscales. Although the HADS \[[@B10-jcm-09-02439],[@B17-jcm-09-02439],[@B52-jcm-09-02439],[@B82-jcm-09-02439],[@B87-jcm-09-02439]\] had a positive rating based on several studies, it may show reduced validity in some populations (e.g., older people).

### 3.5.3. Construct Validity {#sec3dot5dot3-jcm-09-02439}

Construct validity was assessed in all tools. The KOOS \[[@B37-jcm-09-02439],[@B40-jcm-09-02439],[@B73-jcm-09-02439],[@B78-jcm-09-02439],[@B79-jcm-09-02439]\], WOMAC \[[@B8-jcm-09-02439],[@B18-jcm-09-02439],[@B34-jcm-09-02439],[@B63-jcm-09-02439],[@B79-jcm-09-02439],[@B89-jcm-09-02439]\], OKS \[[@B30-jcm-09-02439],[@B42-jcm-09-02439]\], GDS \[[@B73-jcm-09-02439]\], HADS \[[@B10-jcm-09-02439],[@B17-jcm-09-02439],[@B52-jcm-09-02439],[@B82-jcm-09-02439],[@B87-jcm-09-02439]\], SF-36 \[[@B7-jcm-09-02439],[@B8-jcm-09-02439],[@B27-jcm-09-02439],[@B34-jcm-09-02439],[@B35-jcm-09-02439],[@B75-jcm-09-02439],[@B88-jcm-09-02439]\], SF-12 \[[@B7-jcm-09-02439],[@B28-jcm-09-02439],[@B34-jcm-09-02439],[@B38-jcm-09-02439],[@B88-jcm-09-02439]\], and pain by a numeric rating scale (NRS pain) \[[@B83-jcm-09-02439]\] had positive ratings based on some studies. The KSS \[[@B29-jcm-09-02439],[@B70-jcm-09-02439]\] and PCS \[[@B82-jcm-09-02439]\] received indeterminate ratings mostly due to the lack of pre-defined hypotheses and confirmation of less than 75% of the hypotheses. Finally, the HSS \[[@B51-jcm-09-02439],[@B69-jcm-09-02439]\] and STAI \[[@B72-jcm-09-02439]\] obtained negative assessments.

### 3.5.4. Floor/Ceiling Effects {#sec3dot5dot4-jcm-09-02439}

Floor and ceiling effects were evaluated in only 7 (54%) instruments. Based on more than one study, the KOOS \[[@B37-jcm-09-02439],[@B40-jcm-09-02439],[@B73-jcm-09-02439],[@B78-jcm-09-02439],[@B79-jcm-09-02439]\], WOMAC \[[@B8-jcm-09-02439],[@B18-jcm-09-02439],[@B34-jcm-09-02439],[@B63-jcm-09-02439],[@B79-jcm-09-02439],[@B89-jcm-09-02439]\], OKS \[[@B30-jcm-09-02439],[@B42-jcm-09-02439],[@B90-jcm-09-02439]\], SF-36 \[[@B7-jcm-09-02439],[@B8-jcm-09-02439],[@B27-jcm-09-02439],[@B34-jcm-09-02439],[@B35-jcm-09-02439],[@B75-jcm-09-02439],[@B88-jcm-09-02439]\], and SF-12 \[[@B7-jcm-09-02439],[@B28-jcm-09-02439],[@B34-jcm-09-02439],[@B38-jcm-09-02439],[@B88-jcm-09-02439]\] had positive ratings. The HADS \[[@B10-jcm-09-02439],[@B17-jcm-09-02439],[@B52-jcm-09-02439],[@B82-jcm-09-02439],[@B87-jcm-09-02439]\] and HSS \[[@B51-jcm-09-02439],[@B69-jcm-09-02439]\] had indeterminate ratings in nearly all studies because some subscales did not meet the 15% cut-off point.

### 3.5.5. Reliability {#sec3dot5dot5-jcm-09-02439}

Reliability parameters were reported in 11 (85%) instruments. The KOOS \[[@B55-jcm-09-02439]\], OKS \[[@B13-jcm-09-02439],[@B30-jcm-09-02439]\], HSS \[[@B51-jcm-09-02439],[@B69-jcm-09-02439]\], GDS \[[@B73-jcm-09-02439]\], HADS \[[@B10-jcm-09-02439],[@B17-jcm-09-02439],[@B52-jcm-09-02439],[@B82-jcm-09-02439],[@B87-jcm-09-02439]\], PCS \[[@B82-jcm-09-02439]\] and NRS pain \[[@B83-jcm-09-02439]\] had positive ratings in terms of the intra-class correlation coefficient (ICC), generally ranging from 0.7 to 0.9, based on some studies. However, the WOMAC \[[@B63-jcm-09-02439]\], SF-36 \[[@B62-jcm-09-02439]\], and SF-12 \[[@B62-jcm-09-02439]\] had indeterminate ratings based on several studies. The STAI \[[@B72-jcm-09-02439]\] also had indeterminate ratings because of poor reliability for the S-Anxiety subscale. Indeterminate ratings were attributed to coefficients \<0.7 for a number of subscales, sample sizes \<50, and uncertainty of methods used, such as Pearson's correlation ([Table S1](#app1-jcm-09-02439){ref-type="app"}).

### 3.5.6. Agreement {#sec3dot5dot6-jcm-09-02439}

Agreement was evaluated in 5 (38%) tools; namely, KOOS \[[@B40-jcm-09-02439],[@B73-jcm-09-02439],[@B79-jcm-09-02439]\], WOMAC \[[@B63-jcm-09-02439]\], SF-36 \[[@B7-jcm-09-02439],[@B8-jcm-09-02439],[@B27-jcm-09-02439],[@B34-jcm-09-02439],[@B35-jcm-09-02439],[@B75-jcm-09-02439],[@B88-jcm-09-02439]\], SF-12 \[[@B7-jcm-09-02439],[@B28-jcm-09-02439],[@B34-jcm-09-02439],[@B38-jcm-09-02439],[@B88-jcm-09-02439]\] and NRS pain \[[@B83-jcm-09-02439]\]. Only the SF-36 and SF-12 had positive ratings. The KOOS \[[@B40-jcm-09-02439],[@B73-jcm-09-02439],[@B79-jcm-09-02439]\] had indeterminate ratings based on several studies, primarily because of small sample sizes, as did the WOMAC \[[@B63-jcm-09-02439]\]. For KOOS \[[@B55-jcm-09-02439]\] and WOMAC, the calculated standard error of the mean (SEM) and minimal detectable change (MDC) were compared by 0.5 standard deviation (SD), because the minimal important change (MIC) was not defined and these values were less than the estimated MIC.

### 3.5.7. Responsiveness {#sec3dot5dot7-jcm-09-02439}

Responsiveness was examined in almost all tools by various methods. With the definition of responsiveness used in this study, the KOOS \[[@B40-jcm-09-02439],[@B73-jcm-09-02439],[@B79-jcm-09-02439]\], OKS \[[@B13-jcm-09-02439],[@B30-jcm-09-02439],[@B42-jcm-09-02439],[@B90-jcm-09-02439]\], GDS \[[@B73-jcm-09-02439]\], HADS \[[@B10-jcm-09-02439],[@B17-jcm-09-02439],[@B52-jcm-09-02439],[@B82-jcm-09-02439],[@B87-jcm-09-02439]\] and NRS pain \[[@B83-jcm-09-02439]\] had positive ratings for responsiveness to change. In TKA patients, at 6 months, the MIC scores for improvement in pain and physical function for the WOMAC were approximately 23 and 19, respectively, which were higher than the MDC \[[@B79-jcm-09-02439]\]. For the NRS pain, the MIC was less than the MDC \[[@B83-jcm-09-02439]\]. The remaining instruments had indeterminate ratings because only distribution-based methods were used, external clinical criteria or a control ("stable") population to determine whether change had indeed occurred were lacking, and the MIC was not defined.

### 3.5.8. Interpretability {#sec3dot5dot8-jcm-09-02439}

For 5 (38%) instruments, at least 2 types of information were presented to aid interpretability. Interpretability was rated positive for the KOOS \[[@B37-jcm-09-02439],[@B40-jcm-09-02439],[@B73-jcm-09-02439],[@B78-jcm-09-02439],[@B79-jcm-09-02439]\], STAI \[[@B72-jcm-09-02439]\], GDS \[[@B73-jcm-09-02439]\], HADS \[[@B10-jcm-09-02439],[@B17-jcm-09-02439],[@B52-jcm-09-02439],[@B82-jcm-09-02439],[@B87-jcm-09-02439]\] and PCS \[[@B82-jcm-09-02439]\]. The remaining tools had doubtful or no ratings mostly because of presentation of less than 2 types of information.

### 3.5.9. Practical Burden {#sec3dot5dot9-jcm-09-02439}

Practical burden on the patient (time to complete tool, ease of scoring) was assessed for almost all instruments. Only the KSS, HSS, SF-36 and SF-12 had doubtful or negative ratings, which were mainly related to some scoring difficulty.

### 3.5.10. Cultural Adaptation {#sec3dot5dot10-jcm-09-02439}

Transcultural adaptation was not rated precisely because of the great subjectivity and frequently because of lack of clarity in the cross-cultural adaptation process. [Table 3](#jcm-09-02439-t003){ref-type="table"} and [Table A3](#jcm-09-02439-t0A3){ref-type="table"} show the cultural translations/adaptations of each tool.

3.6. Psychometric Qualities of Physical Tests {#sec3dot6-jcm-09-02439}
---------------------------------------------

### 3.6.1. Reliability {#sec3dot6dot1-jcm-09-02439}

Reliability parameters were reported for almost all physical tests. The strength testing of knee flexor/extensor by isometric or isokinetic dynamometer (strength) \[[@B87-jcm-09-02439]\], 6-min Walk Test (6MWT) \[[@B9-jcm-09-02439],[@B54-jcm-09-02439],[@B91-jcm-09-02439]\], Five Times Sit-To-Stand Test (5STS test) \[[@B43-jcm-09-02439],[@B64-jcm-09-02439],[@B92-jcm-09-02439]\], Timed Up and Go Test (TUG) \[[@B2-jcm-09-02439],[@B43-jcm-09-02439],[@B54-jcm-09-02439],[@B91-jcm-09-02439],[@B93-jcm-09-02439]\] and Stair Climbing Time (SCT) \[[@B6-jcm-09-02439],[@B94-jcm-09-02439],[@B95-jcm-09-02439]\] test had positive ratings for both intra- and inter-tester reliability. The Pressure Pain Threshold (PPT) \[[@B86-jcm-09-02439]\] had a positive rating for intra-tester reliability, but inter-tester reliability was not assessed. The other physical tests had doubtful reliability.

### 3.6.2. Responsiveness {#sec3dot6dot2-jcm-09-02439}

Only strength \[[@B87-jcm-09-02439]\], PPT \[[@B86-jcm-09-02439]\], 6MWT \[[@B9-jcm-09-02439],[@B54-jcm-09-02439],[@B91-jcm-09-02439]\] and TUG \[[@B2-jcm-09-02439],[@B43-jcm-09-02439],[@B54-jcm-09-02439],[@B91-jcm-09-02439],[@B93-jcm-09-02439]\] tools had a positive rating for responsiveness. The others were doubtful for gait velocity at self-paced and 10-m Walk Test (10MWT) at a fast pace or undetermined for the remaining tests.

### 3.6.3. Interpretability {#sec3dot6dot3-jcm-09-02439}

For 6 (50%) tests, interpretability was rated positive for the knee range of motion \[[@B48-jcm-09-02439],[@B55-jcm-09-02439]\], strength \[[@B87-jcm-09-02439]\], PPT \[[@B86-jcm-09-02439]\], 6MWT \[[@B9-jcm-09-02439],[@B54-jcm-09-02439],[@B91-jcm-09-02439]\], 5STS \[[@B43-jcm-09-02439],[@B64-jcm-09-02439],[@B92-jcm-09-02439]\] and TUG \[[@B2-jcm-09-02439],[@B43-jcm-09-02439],[@B54-jcm-09-02439],[@B91-jcm-09-02439],[@B93-jcm-09-02439]\] tools. The remaining tools had doubtful or no ratings mostly due to lack of MDC.

### 3.6.4. Practical Burden {#sec3dot6dot4-jcm-09-02439}

Practical burden on the patient (time to administer, ease of scoring) was assessed for almost all instruments. Only strength had negative ratings related to time to administer. Physical activity level with average steps/day measured by accelerometry (actimetry) also had a negative rating related to ease of scoring, with some signal processing difficulty.

3.7. Overall Score {#sec3dot7-jcm-09-02439}
------------------

Among the condition-specific PROMs, the OKS, KOOS and WOMAC had the highest overall scores with 10, 9 and 8 positive ratings respectively over the 12 criteria investigated. Concerning generic tools, the SF-36 and SF-12 obtained the highest overall score, with 6 positive ratings. For patient-specific tools, the GDS and HADS seem appropriate, with an overall positive rating of 9 and 8, respectively ([Table 3](#jcm-09-02439-t003){ref-type="table"} and [Figure 2](#jcm-09-02439-f002){ref-type="fig"}).

Regarding physical tests, some tests appeared to be quite robust in terms of psychometric properties---strength, PPT, 6MWT, 5STS, TUG tools---with an overall score ≥6/7. However, some tests lacked clinimetric studies: The Active Straight Leg Raise (ASLR), gait velocity, 10MWT, electromyography and actimetry, with an overall score ≤2 ([Figure 3](#jcm-09-02439-f003){ref-type="fig"} and [Table A5](#jcm-09-02439-t0A5){ref-type="table"}).

4. Discussion {#sec4-jcm-09-02439}
=============

In this study, we examined and compared the quality of the measurement properties of outcome measures (patient-reported and for the first time, physical tests) assessing rehabilitation outcomes for patients with knee OA undergoing TKA. There are 3 main findings in this review. First, a wide variety of PROMs are applied to measure outcomes in rehabilitation after knee arthroplasty, but only 3 (KOOS, WOMAC and OKS) have undergone an extensive validation process in knee OA before and/or after TKA. Second, important measurement attributes for evaluative instruments such as reproducibility, responsiveness to clinical change and definition of the MIC are still scarcely evaluated. Third, some physical tests were well evaluated (TUG, 5STS test, 6MWT, PPT) but others not at all (actimetry, electromyography, ASLR).

Of the 13 tools applied in knee arthroplasty rehabilitation, the KOOS, WOMAC and OKS have been completely studied for their measurement properties, including content validity, reliability, construct validity, responsiveness, and floor and ceiling effects. The GDS seems valid in younger populations but in view of the mean age of TKA patients may not be the best assessment and the HADS may be preferred. The Hamilton Depression Rating Scale (HDRS) is frequently used as a primary or secondary outcome, but no studies have been carried out in this type of population; nevertheless its validity has been assessed in a depressive population \[[@B96-jcm-09-02439]\]. In the same way, for the ASLR, although frequently used, only one study used it in this type of population \[[@B93-jcm-09-02439]\] but not really in terms of its psychometric properties. Nevertheless, clinimetric properties of the ASLR have been widely assessed in chronic low back pain \[[@B97-jcm-09-02439]\].

Another key finding from this study is the persistent lack of essential requisites for evaluative instruments. Because evaluative PROMs are used to assess change in patients over time, these measures need to have high responsiveness and high reproducibility \[[@B98-jcm-09-02439]\]. These instruments must be able to identify a change if it occurred, and in this case be able to establish that it is beyond the range of measurement error. Therefore, the agreement parameter is vital (and preferred over the reliability parameter) because this concerns the absolute measurement error. The measurement error is an essential data to distinguish whether the change measured is relevant or not. The MDC can be estimated from the measurement error, and can be compared to the MIC. Knowing the MDC, the amount of measurement error as well as how these relate to the MIC provides insight into the meaning of values changes from the instrument \[[@B33-jcm-09-02439]\].

In this review, as in the study of Veenhof et al. \[[@B23-jcm-09-02439]\], estimates of agreement were reported less frequently than were estimates of reliability. Of the 13 instruments, 6 (46%) reported a positively rated reliability parameter and only 2 (15%) presented an agreement parameter. Researchers tend to use more reliability parameters than agreement parameters \[[@B98-jcm-09-02439]\]. Agreement parameters is a psychometric property tend to be neglected in clinimetric studies in the medical sciences \[[@B98-jcm-09-02439]\]. The other issue lay in determining the responsiveness of the instruments for which a definition of MDC is missing. According to Alviar et al. \[[@B24-jcm-09-02439]\], "most studies examined responsiveness to clinical change by estimating effect sizes, standardized response means, and the t statistic, which could be affected by sample size and sample variation". In this review, as in Alviar et al. ten years ago, only a few studies defined the MDC to allow for meaningful interpretation of the obtained scores. Defining what constitutes a clinically meaningful change should remain a priority for future clinimetric studies.

Although the HDRS has been widely used to evaluate depression, to our knowledge no clinimetric study has been done in OA patients. Moreover, the criticism regarding its reliability has been growing the last few years. A recent review of Bagby et al. \[[@B96-jcm-09-02439]\] showed that the HDRS is ''... psychometrically flawed...''and the authors suggested its revision.

Some physical tests were well evaluated, but others not at all. Actimetry is a recent technology in full expansion, having for a main interest allowing an evaluation of the functional abilities of the patient in everyday life. However, we lack consensus on the measurement method, signal processing and results interpretation (number of steps, activity counts, duration of activity at different intensity levels). Mainly, the lack of consensus is from the signal processing and extracted data but not from interpretation of these data for which there is a known threshold of "normality". Studies of this subject seem necessary. Also, the tests presented here (with the exception of strength, EMG and actimetry) are simple to implement in everyday clinical practice (see necessary equipment in [Table A1](#jcm-09-02439-t0A1){ref-type="table"} and [Table A5](#jcm-09-02439-t0A5){ref-type="table"}). However, although most have psychometric properties clearly evaluated in our population, the rules of good practices must be respected when administering these performance-based tests (see [Table A1](#jcm-09-02439-t0A1){ref-type="table"}).

This study has several limitations. Regarding the large number of studies of TKA patients, only instruments used in CCTs or RCTs were included, so pertinent tools might have been missed. The definitions approaches and methods in assessing the attributes varied among studies. We lack a gold standard to assess the measurement properties of PROMs \[[@B88-jcm-09-02439]\]. The review included only studies in which measurement properties were assessed with classical response theory, and therefore recent studies using relatively newer approaches (e.g., IRT) might have been missed. The IRT method is progressively becoming a prominent tool in rehabilitation research since it facilitates the evaluation of the quality of psychometric properties of some instruments. However, we still lack explicit criteria for quality evaluation of the methods and results of studies using IRT models. The unfavorable or indeterminate ratings a tool received could be due to flaws in study methods, and not necessarily deficiency of the tool per se. In addition, because some tools have been extensively studied (e.g., WOMAC, SF-36), they had varied ratings per measurement attribute as compared with others with only one or a few clinimetric studies but positive ratings for the attributes. Negative results in clinimetric studies obtained and not published (publication bias) is another limitation, which might have precluded the inclusion of these studies.

5. Conclusions {#sec5-jcm-09-02439}
==============

We compared the measurement attributes of the various outcomes applied in studies of rehabilitation after TKA with a view to facilitating the choice of the most appropriate instruments for studies of patients with knee OA who are undergoing TKA. Physical tests were reviewed for the first time in TKA population. Our analysis suggests that strength, PPT, 6MWT, 5STS and TUG tools are notable; the 6MWT, TUG being however the most extensively validated and therefore possibly the most appropriate to use. Overall, regarding PROMs our findings corroborate results from previous studies suggesting that the KOOS, WOMAC, OKS, HADS and SF-36 are the most comprehensively tested tools in this population and are worth considering. Nevertheless, as already demonstrated more rigorous evaluations in key areas, such as reproducibility, responsiveness to clinical change, and MIC, are still needed to make stronger recommendations. By differentiating the assessment field of each tool, we may potentially recommend the KOOS for the most relevant as à condition specific questionnaire; the HADS as a patient specific and finally the SF-36 as a generic one. Nevertheless, other promising assessments (e.g., actimetry) lack validation and require rigorous studies to be used as a core set of outcomes in future studies. This review could serve as a basis for future studies, being a guarantee of quality.

The following are available online at <https://www.mdpi.com/2077-0383/9/8/2439/s1> and detail the Experimental Section, Research algorithm S1: Search terms used in databases, Table S1: Checklist for rating the psychometric quality of self-assessment tools, Table S2: Checklist for rating the psychometric quality of physical tools.

###### 

Click here for additional data file.
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###### 

Description of performance-based tests of physical function.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Performance-Based Tests   Equipment/Space                                                                                                                                                       Measure        Description/Instructions
  ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Walking tests**                                                                                                                                                                                              

  10MWT                     Stopwatch 10 m (33 ft) marked walkway with an additional 2 m at each end for acceleration and deceleration.                                                           Speed (m/s)    Walk as quickly but as safely as possible to a mark 10 m away starting off launched.\
                                                                                                                                                                                                                 Regular walking aid is allowed.

  6MWT                      Timer/stopwatch Flat, hard-surfaced indoor walkway of 30 m marked with 1 m intervals. Chair or stool for resting                                                      Distance (m)   The maximum distance that can be walked over a 6-min interval is recorded. Rest periods are allowed but included in the time Standardized encouragement (e.g., "keep going you are doing really well") can be given at minute intervals. Regular walking aid is allowed. Practice test not needed in most clinical settings but if performed then at least 1 h rest should be allowed before the second test. The greatest distance is then recorded.

  **Sit-to-stand tests**                                                                                                                                                                                         

  5STS test                 Timer/stopwatch Straight back chair preferably without arms with approximately 43 cm (17 inch) seat height                                                            Time (s)       From the sitting position with arms crossed at chest, stand up (sit down) as fast as possible for a total of five stands (i.e., test ends in standing). Fastest time of two trials is recorded in seconds. Same chair is required for re-testing.

  TUG                       Stopwatch Standard chair with armrests (approx. 46 cm (18 inch) seat height with 65 cm (26 inch) arm rest height) Marked 3 m (10 ft) walkway with turn point at end   Time (s)       Time to rise from a standard armchair, walk as quickly but as safely as possible distance of 3 m, turn, walk back to the chair and sit down. Usual footwear and regular walking aids allowed and recorded. Fastest of two trials is recorded in seconds. Same chair is needed for re-testing.

  **Stair tests**                                                                                                                                                                                                

  SCT                       Stopwatch Flight of 12 stairs with 18 cm (7 inch) step height and handrails                                                                                           Time (s)       Ascend and descend flight of 12 stairs as quickly as safe and comfortable. One handrail allowed but encouraged to only use legs. Total time to ascend and descend steps for one trial is recorded to nearest 100th second.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

See [Table 2](#jcm-09-02439-t002){ref-type="table"} for abbreviations.

jcm-09-02439-t0A2_Table A2

###### 

PEDro scores for included studies in this review.

  Reference                                              1 \*   2   3   4   5   6   7   8   9   10   11   Total (/10)   Quality
  ------------------------------------------------------ ------ --- --- --- --- --- --- --- --- ---- ---- ------------- ----------
  Winters et al., 2014 \[[@B34-jcm-09-02439]\]           Y      0   0   0   0   0   0   1   1   1    1    4             Moderate
  Smith et al., 2014 \[[@B35-jcm-09-02439]\]             Y      0   0   1   0   0   0   1   1   1    1    5             Moderate
  Bade et al., 2014 \[[@B36-jcm-09-02439]\]              Y      0   0   1   0   0   0   1   1   1    1    5             Moderate
  Abdel et al., 2014 \[[@B37-jcm-09-02439]\]             Y      1   1   1   0   0   0   1   1   1    1    7             High
  Jenkins et al., 2014 \[[@B38-jcm-09-02439]\]           Y      1   1   1   0   0   0   1   1   1    1    7             High
  Thomas et al., 2014 \[[@B39-jcm-09-02439]\]            Y      0   0   1   0   0   0   1   1   1    1    5             Moderate
  Huber et al., 2015 \[[@B40-jcm-09-02439]\]             Y      1   1   1   0   0   0   1   1   1    1    7             High
  Calatayud et al., 2017 \[[@B41-jcm-09-02439]\]         Y      1   1   1   0   0   0   1   1   1    1    7             High
  Bistolfi et al., 2017 \[[@B42-jcm-09-02439]\]          Y      0   0   1   0   0   0   1   0   1    1    4             Moderate
  Hadlandsmyth et al., 2017 \[[@B43-jcm-09-02439]\]      Y      0   0   0   0   0   0   1   1   1    1    4             Moderate
  Cooper et al., 2017 \[[@B44-jcm-09-02439]\]            Y      0   0   1   0   0   0   1   1   1    1    5             Moderate
  Bonnefoy-Mazure et al., 2017 \[[@B45-jcm-09-02439]\]   Y      0   0   1   0   0   0   1   1   1    1    5             Moderate
  Loyd et al., 2017 \[[@B46-jcm-09-02439]\]              Y      1   1   1   0   0   0   1   1   1    1    7             High
  Lin et al., 2018. \[[@B47-jcm-09-02439]\]              Y      1   1   1   0   0   0   1   1   1    1    7             High
  Husby et al., 2018 \[[@B48-jcm-09-02439]\]             Y      1   0   1   0   0   0   1   1   1    1    6             High
  Paravlic et al., 2019 \[[@B49-jcm-09-02439]\]          Y      1   1   1   0   0   0   1   1   1    1    7             High
  Indelli et al., 2019 \[[@B50-jcm-09-02439]\]           Y      0   0   1   0   0   1   1   1   1    1    6             High
  Jiang et al., 2019 \[[@B51-jcm-09-02439]\]             Y      0   0   1   0   0   0   1   1   1    1    5             Moderate
  Liljensøe et al., 2019 \[[@B52-jcm-09-02439]\]         Y      1   1   1   1   0   0   0   1   1    1    7             High
  Skoffer et al., 2019 \[[@B53-jcm-09-02439]\]           Y      1   1   1   1   0   0   1   1   1    1    8             High

\* Not included in total score; Y = yes; N = No; 1 = eligibility criteria; 2 = random allocation; 3 = concealed allocation; 4 = similarity groups at baseline; 5 = blinding subjects; 6 = blinding therapists; 7 = blinding assessors; 8 = outcome obtained in \>85% of the subjects; 9 = intention to treat analysis; 10 = between-group statistical comparison; 11 = point estimates and measures of variability.

jcm-09-02439-t0A3_Table A3

###### 

Cultural translation/adaptation for each tool.

  Tool                     Translations/Adaptations
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Condition-specific**   
  KOOS                     Available in English. The KOOS has been translated into Arabic, Austria-German, Bengali, Czech, Chinese, Croatian, Dutch, Danish, Estonian, Finnish, Filipino, French, Greek, Icelandic, Italian, Japanese, Korean, Latvian, Lithuanian, Malay, Norwegian, Persian, Portuguese, Polish, Romanian, Russian, Slovakian, Singapore English, Slovenian, Spanish, Swedish, Thai, Turkish, Ukrainian, Vietnamese, Welsh, and Zulu.
  WOMAC                    Available in English. The WOMAC has been translated into Arabic, German, French, Hebrew, Italian, Japanese, Singapore, Spanish, Korean, and Swedish.
  KSS                      Available in English. The KSS has been translated into French, German, Chinese, Portuguese, Dutch, and Turkish.
  OKS                      Available in English. The KSS has been translated into French, German, Chinese, Portuguese, Dutch, and Turkish. French, Portuguese, German, Danish, Thai, Estonian, Finnish, Greek, Indonesian, Japanese, Chinese, Russian, Arabic, Serbian, Swedish, Italian, Turkish, Malay, Welsh, Polish, Korean, Spanish.
  HSS                      Available in English and French
  **Patient-specific**     
  HDRS                     Available in English. The HDRS has been translated into many languages such as Arabic, Bulgarian, Croatian, French, German, Georgian, Hebrew, Italian, Japanese, Russian, Spanish,
  STAI                     Available in English. The STAI has been translated into more than 48 languages
  GDS                      Available in English. The GDS has been translated into Arabic, Chinese, Creole, Danish, Dutch, Farsi, French, French Canadian, German, Greek, Hebrew, Hindi, Hungarian, Icelandic, Italian, Japanese, Korean, Lithuanian, Malay, Maltese, Norwegian, Portuguese, Romanian, Russian, Serbian, Spanish, Swedish, Thai, Turkish, Vietnamese, and Yiddish.
  HADS                     Available in English, as well as all other languages of Western Europe and many of Eastern Europe and Scandinavia, along with some African and Far East languages, including Arabic, Chinese, Danish, Dutch, Finnish, French, German, Hebrew, Hungarian, Italian, Japanese, Korean, Norwegian, Portuguese, Spanish, Swedish, Thai, and Urdu.
  **Generic**              
  SF-36                    Available in English. The SF-36 has been translated into more than 161 languages (Chinese, Dutch, Danish, French, Iranian, Italian, Japanese, Kiswahili, Norwegian, Portuguese, Spanish, and Swedish)
  SF-12                    Available in English. The SF-36 has been translated into more than 141 languages.
  PCS                      Available in English and French
  NRS pain                 No translation needed.

See [Table 2](#jcm-09-02439-t002){ref-type="table"} for abbreviations.

jcm-09-02439-t0A4_Table A4

###### 

Summary of the quality assessment of the patient-reported outcome measures included.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tool (References)                                                                                                                                     Time to Administer   Ease of Scoring   Readability and Comprehension   Content Validity   Internal Consistency   Construct Validity   Floor/Ceiling Effect   Reliability   Agree-ment   Respon-Siveness   Interpret-Ability   MDC~95~        Positively Rated Qualities, no
  ----------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ----------------- ------------------------------- ------------------ ---------------------- -------------------- ---------------------- ------------- ------------ ----------------- ------------------- -------------- --------------------------------
  **Condition-specific**                                                                                                                                                                                                                                                                                                                                                                             

  KOOS \[[@B37-jcm-09-02439],[@B40-jcm-09-02439],[@B73-jcm-09-02439],[@B78-jcm-09-02439],[@B79-jcm-09-02439]\]                                          \+                   \+                                                \+                 \+                     \+                   \+ §§§                 \+            ø            \+                \+                                 9

  WOMAC \[[@B8-jcm-09-02439],[@B18-jcm-09-02439],[@B34-jcm-09-02439],[@B63-jcm-09-02439],[@B79-jcm-09-02439],[@B89-jcm-09-02439]\]                      \+                   \+                \+                              \+                 ø                      \+                   \+ §                   ø             ø            \+                ø                   \+\            8
                                                                                                                                                                                                                                                                                                                                                                                      0.5--1.3 pts   

  KSS \[[@B29-jcm-09-02439],[@B70-jcm-09-02439]\]                                                                                                       \-                   \-                \+                              ø                  \+ \*                  ø                                                                                                                           2

  OKS \[[@B13-jcm-09-02439],[@B30-jcm-09-02439],[@B42-jcm-09-02439],[@B90-jcm-09-02439]\]                                                               \+                   \+                \+                              \+                 \+                     \+                   \+ §§§§                \+            ø            \+                ø                   \+\            10
                                                                                                                                                                                                                                                                                                                                                                                      4.15 pts       

  HSS \[[@B51-jcm-09-02439],[@B69-jcm-09-02439]\]                                                                                                       \+                   ø                 \+                                                 \+                     \-                   ø                      \+                                                                              3

  **Patient-specific**                                                                                                                                                                                                                                                                                                                                                                               

  HDRS                                                                                                                                                                                                                                                                                                                                                                                               0

  STAI \[[@B72-jcm-09-02439]\]                                                                                                                          \+                   \+                                                \+                 \+                     \-                                          ø \#                       ø ˩               \+                                 5

  GDS \[[@B73-jcm-09-02439]\]                                                                                                                           \+                   \+                \+                              \+                 \+                     \+                                          \+                         \+                \+                                 9

  HADS \[[@B10-jcm-09-02439],[@B17-jcm-09-02439],[@B52-jcm-09-02439],[@B82-jcm-09-02439],[@B87-jcm-09-02439]\]                                          \+                   \+                ø                               \+                 \+ \*\*                \+                   ø                      \+                         \+                \+                                 8

  **Generic**                                                                                                                                                                                                                                                                                                                                                                                        

  SF-36 \[[@B7-jcm-09-02439],[@B8-jcm-09-02439],[@B27-jcm-09-02439],[@B34-jcm-09-02439],[@B35-jcm-09-02439],[@B75-jcm-09-02439],[@B88-jcm-09-02439]\]   \+                   \-                                                ø                  \+                     \+                   \+ § and §§            ø             \+           ø                 ø                   \+\            6
                                                                                                                                                                                                                                                                                                                                                                                      2.0--7.8 pts   

  SF-12 \[[@B7-jcm-09-02439],[@B28-jcm-09-02439],[@B34-jcm-09-02439],[@B38-jcm-09-02439],[@B88-jcm-09-02439]\]                                          \+                   \-                                                ø                  \+                     \+                   \+ § and §§            ø             \+           ø                 ø                   \+\            6
                                                                                                                                                                                                                                                                                                                                                                                      3.8--5.4 pts   

  PCS \[[@B82-jcm-09-02439]\]                                                                                                                           \+                   \+                                                ø                  \+                     ø                                           \+                                           \+                                 5

  NRS pain \[[@B83-jcm-09-02439]\]                                                                                                                      \+                   \+                                                                                          \+                                          \+            \-           \+                ø                   \+\            6
                                                                                                                                                                                                                                                                                                                                                                                      1.33 pts       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MDC~95~ = minimal detectable change at the 95% confidence level; + = positive; - = negative; ø = doubtful; pts = points; see [Table 2](#jcm-09-02439-t002){ref-type="table"} for additional abbreviations. \* ø for the functional subscale; \*\* May have reduced validity in some populations (e.g., older people). § Floor effect; §§ Ceiling effect; §§§ Floor effect for sports and recreation subscale; §§§§ floor and ceiling effect for some individual items but not at the scale level. \# - for S-Anxiety. ˩ S-Anxiety more responsive to change than T-Anxiety.
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###### 

Summary of the quality assessment of the included physical tests.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Physical Test (References)                                                                                      Domains ˥                              Necessary Equipment ǂ                         Time to Administer (min)   Ease of Scoring   Intra-Tester Reliability   Inter-Tester Reliability   Respon-Siveness   Interpret-Ability   MDC~95~         Positively Rated Qualities, no
  --------------------------------------------------------------------------------------------------------------- -------------------------------------- --------------------------------------------- -------------------------- ----------------- -------------------------- -------------------------- ----------------- ------------------- --------------- --------------------------------
  **Analytic tests**                                                                                                                                                                                                                                                                                                                                            

  Knee ROM \[[@B90-jcm-09-02439],[@B99-jcm-09-02439]\]                                                            Articular limitation                   Goniometer                                    \+ \< 5                    \+                ø                          ø                                            \+                  \+\             4
                                                                                                                                                                                                                                                                                                                                                6.6--10 °       

  ASLR \[[@B93-jcm-09-02439]\]                                                                                    Quadriceps strength                    Goniometer or measuring tape                  \+ \< 5                    \+                                                                                                                            2

  Strength \[[@B87-jcm-09-02439]\]                                                                                Lower extremity strength               Isometric or isokinetic dynamometer           −15--30                    \+                \+                         \+                         \+                \+                  \+\             6
                                                                                                                                                                                                                                                                                                                                                5.1--9.3% \*    

  EMGs                                                                                                            Neuromotor activation                  Surface electromyography                      −15--30                    \-                                                                                                                            0

  PPT \[[@B86-jcm-09-02439]\]                                                                                     Knee pain measure                      Handheld pressure algometer                   \+ \< 5                    \+                \+                                                    \+                \+                  \+\             6
                                                                                                                                                                                                                                                                                                                                                1.19--1.26 lb   

  **Performance-based tests**                                                                                                                                                                                                                                                                                                                                   

  **Walking tests**                                                                                                                                                                                                                                                                                                                                             

  Gait velocity \[[@B100-jcm-09-02439],[@B101-jcm-09-02439]\]                                                     Patients' functional mobility          Stopwatch, 30 m hallway                       \+ \< 5                    \+                ø                          ø                          ø                 ø                   ø               2

  10MWT \[[@B91-jcm-09-02439],[@B102-jcm-09-02439]\]                                                              Patients' functional mobility          Stopwatch, 15 m hallway                       \+ \< 5                    \+                ø                          ø                          ø                 ø                                   2

  6MWT \[[@B89-jcm-09-02439],[@B91-jcm-09-02439],[@B102-jcm-09-02439]\]                                           Patients' functional mobility          30 m course marked off in meters, stopwatch   \+ 10                      \+                \+                         \+                         \+                \+                  \+\             6
                                                                                                                                                                                                                                                                                                                                                61.34 m         

  Actimetry \[[@B103-jcm-09-02439]\]                                                                              Patients' physical activity            Accelerometer                                 \- or NA                   \-                ø                          ø                                            ø                                   0

  **Sit-to-stand tests**                                                                                                                                                                                                                                                                                                                                        

  5STS test \[[@B84-jcm-09-02439],[@B104-jcm-09-02439],[@B105-jcm-09-02439]\]                                     Lower extremity strength and balance   Chair, stopwatch                              \+ \< 5                    \+                \+                         \+                                           \+                  \+\             6
                                                                                                                                                                                                                                                                                                                                                2.1--2.38 s     

  TUG \[[@B91-jcm-09-02439],[@B92-jcm-09-02439],[@B94-jcm-09-02439],[@B102-jcm-09-02439],[@B104-jcm-09-02439]\]   Patients' functional mobility          Armchair, stopwatch                           \+ \< 5                    \+                \+                         \+                         \+                \+                  \+\             7
                                                                                                                                                                                                                                                                                                                                                1.10--2.27 s    

  **Stair tests**                                                                                                                                                                                                                                                                                                                                               

  SCT\                                                                                                            Patients' functional mobility          Regular stairwell, stopwatch                  \+ \< 5                    \+                \+                         \+                                                               \+\             5
  \[[@B27-jcm-09-02439],[@B88-jcm-09-02439],[@B95-jcm-09-02439]\]                                                                                                                                                                                                                                                                               3.2--5.49 s     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OA = osteoarthritis; TKA = total knee arthroplasty; MDC~95~ = minimal detectable change at the 95% confidence level; + = positive; - = negative; ø = doubtful; NA = not applicable; see [Table 2](#jcm-09-02439-t002){ref-type="table"} for additional abbreviations. ˥ Domains: domain(s) explored by the test; ǂ see [Table A1](#jcm-09-02439-t0A1){ref-type="table"} for more details about equipment, space and instructions; \* Standard error of measurement (SEM).

![PRISMA flowchart diagram of the search process. RCT, randomized controlled trial; CCT, clinical controlled trial; TKA, total knee arthroplasty.](jcm-09-02439-g001){#jcm-09-02439-f001}

![Summary of the quality assessment of patient-reported outcome measures included. MDC~95~ = minimal detectable change at the 95% confidence level; see [Table 2](#jcm-09-02439-t002){ref-type="table"} for additional abbreviations.](jcm-09-02439-g002){#jcm-09-02439-f002}

![Summary of the quality assessment of the included physical tests. MDC~95~ = minimal detectable change at the 95% confidence level; see [Table 2](#jcm-09-02439-t002){ref-type="table"} for additional abbreviations.](jcm-09-02439-g003){#jcm-09-02439-f003}
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###### 

Articles included in the review.

  Author                                           Year of Publication   Country       Journal §                                 Sample Size          Number of Centers, Study Design   Primary Outcome                                                       PEDro Score˥
  ------------------------------------------------ --------------------- ------------- ----------------------------------------- -------------------- --------------------------------- --------------------------------------------------------------------- --------------
  Winters et al. \[[@B34-jcm-09-02439]\]           2014                  USA           Knee                                      nE = 35, nC = 23     1, CCT                            Quadriceps and hamstrings isometric strength assessment               4
  Smith et al. \[[@B35-jcm-09-02439]\]             2014                  USA           J Arthroplasty                            nE = 13, nC = 11     1, CCT                            Quadriceps muscle strength by isokinetic dynamometer                  5
  Bade et al. \[[@B36-jcm-09-02439]\]              2014                  USA           Am J Phys Med Rehabil                     nE = 34, nC = 30     1, RCT                            Knee ROM                                                              5
  Abdel et al. \[[@B37-jcm-09-02439]\]             2014                  USA           Clin Orthop Relat Res                     nE = 20, nC = 20     1, RCT                            KSS, KOOS, SF-12                                                      7
  Jenkins et al. \[[@B38-jcm-09-02439]\]           2014                  USA           J Bone Joint Surg Am                      nE = 60, nC = 60     1, RCT                            Quadriceps isometric strength assessment                              7
  Thomas et al. \[[@B39-jcm-09-02439]\]            2014                  USA           Knee                                      nE = 10, nC = 10     1, CCT                            Quadriceps and hamstrings isometric strength assessment               5
  Huber et al. \[[@B40-jcm-09-02439]\]             2015                  Switzerland   BMC Musculoskelet Disord                  nE = 22, nC = 23     1, RCT                            CST                                                                   7
  Calatayud et al. \[[@B41-jcm-09-02439]\]         2017                  Spain         Knee Surg Sports Traumatol Arthrosc       nE = 25, nC = 25     1, RCT                            WOMAC                                                                 7
  Bistolfi et al. \[[@B42-jcm-09-02439]\]          2017                  Italy         Knee Surgery Sports Traummatol Arthrosc   nE = 23, nC = 44     1, CCT                            HDRS                                                                  4
  Hadlandsmyth et al. \[[@B43-jcm-09-02439]\]      2017                  USA           Psychol Health Med                        nE = 173, nC = 173   1, RCT                            NRS pain                                                              4
  Cooper et al. \[[@B44-jcm-09-02439]\]            2017                  USA           J Orthop Res                              nE = 62, nC = 62     1, CCT                            KOOS, gait velocity and physical activity level using accelerometry   5
  Bonnefoy-Mazure et al. \[[@B45-jcm-09-02439]\]   2017                  Switzerland   J Arthroplasty                            nE = 79, nC = 32     1, CCT                            Gait velocity and knee ROM                                            5
  Loyd et al. \[[@B46-jcm-09-02439]\]              2017                  USA           Phys. Ther                                nE = 84, nC = 78     4, RCT                            Strength testing by isokinetic dynamometer                            7
  Lin et al. \[[@B47-jcm-09-02439]\]               2018                  Taiwan        J. Clin. Nurs                             nE = 100, nC = 100   1, RCT                            KOOS                                                                  7
  Husby et al. \[[@B48-jcm-09-02439]\]             2018                  Norway        Eur J Phys Rehabil Med                    nE = 21, nC = 20     1, RCT                            Quadriceps and hamstring muscle strength                              6
  Paravlic et al. \[[@B49-jcm-09-02439]\]          2019                  Slovenia      PLoS ONE                                  nE = 17, nC = 17     1, RCT                            Quadriceps and hamstring muscle strength                              7
  Indelli et al. \[[@B50-jcm-09-02439]\]           2019                  USA           Knee Surg Sports Traumatol Arthrosc       nE = 50, nC = 50     1, RCT                            ROM, KSS, OKS                                                         6
  Jiang et al. \[[@B51-jcm-09-02439]\]             2019                  China         Orthop Surg                               nE = 109, nC = 147   1, CCT                            NRS pain, KSS, ROM                                                    5
  Liljensøe et al. \[[@B52-jcm-09-02439]\]         2019                  Denmark       Scand J. Surg                             nE = 38, nC = 38     1, RCT                            SF-36                                                                 7
  Skoffer et al. \[[@B53-jcm-09-02439]\]           2019                  Danmark       Clin Rehabil                              nE = 30, nC = 29     1, CCT                            5STS test                                                             8

E = experimental; C = control; RCT = randomized controlled trial; CCT = clinical controlled trial §. See [Table 2](#jcm-09-02439-t002){ref-type="table"} for additional abbreviations. Short name of the journal in which the article was published. ˥ PEDro score: sum of PEDro (Physiotherapy Evidence Database) scale item scores (see [Table A2](#jcm-09-02439-t0A2){ref-type="table"} for details on scores).

jcm-09-02439-t002_Table 2

###### 

Summary of knee osteoarthritis (OA) outcomes used in included articles.

  Abbreviation         Full Name                                                                         Used as Primary or Secondary Outcomes   Number of Times Used
  -------------------- --------------------------------------------------------------------------------- --------------------------------------- ----------------------
  **Questionnaires**                                                                                                                             
  KOOS                 Knee injury and Osteoarthritis Outcomes Score                                     Primary                                 6
  WOMAC                Western Ontario and McMaster Universities Osteoarthritis index                    Primary                                 2
  KSS                  New Knee Society Score                                                            Primary                                 4
  OKS                  Oxford Knee Score                                                                 Primary                                 1
  HSS                  Hospital for Special Surgery                                                      Secondary                               1
  HDRS                 Hamilton Depression Rating Scale                                                  Primary and secondary                   1
  STAI                 State-Trait Anxiety Index                                                         Secondary                               2
  GDS                  Geriatric Depression Scale                                                        Secondary                               2
  HADS                 Hospital Anxiety and Depression Scale                                             Secondary                               1
  SF-36                MOS Short Form 36                                                                 Primary and secondary                   6
  SF-12                MOS Short Form 12                                                                 Secondary                               2
  PCS                  Pain Catastrophizing Score                                                        Secondary                               2
  NRS pain             Pain intensity by Numeric Rating Scale                                            Primary and secondary                   8
  **Physical tests**                                                                                                                             
  Knee ROM             Knee Range Of Motion                                                              Primary and secondary                   8
  ASLR                 Active Straight Leg Raise                                                         Secondary                               1
  Strength             Strength testing of knee flexor/extensor by isometric or isokinetic dynamometer   Primary and secondary                   8
  EMG                  Quadriceps/hamstrings co-activation and on/off timing using electromyography      Secondary                               1
  PPT                  Pressure Pain Threshold                                                           Secondary                               1
  Gait velocity        Gait Velocity (self-paced)                                                        Primary and secondary                   4
  10MWT                Maximum walking speed/10-m walk test (fast-paced)                                 Secondary                               1
  6MWT                 Six-Minute Walk test                                                              Secondary                               4
  Actimetry            Physical activity level with average steps/day using accelerometry                Primary and secondary                   2
  5STS test            Five Times Sit-To-Stand Test                                                      Primary and secondary                   4
  TUG                  Timed Up and Go Test                                                              Primary and secondary                   6
  SCT                  Stair Climbing Time                                                               Secondary                               2

jcm-09-02439-t003_Table 3

###### 

Description of patient-reported outcome measures used for patient with knee OA undergoing total knee arthroplasty.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tool (References)                                                                                                                                       Target Population \#   Domains ˥                                                                                               No. of Scales ˩   No. of Items   No. of Response Options   Range of Scores                                  Time to Administer (min)   Mode of Administration            Cultural/Adaptation ǂ   Copyright
  ------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------------------------------------------------------------------------------------------- ----------------- -------------- ------------------------- ------------------------------------------------ -------------------------- --------------------------------- ----------------------- -----------
  **Condition-specific**                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  KOOS \[[@B54-jcm-09-02439],[@B55-jcm-09-02439],[@B56-jcm-09-02439],[@B57-jcm-09-02439],[@B58-jcm-09-02439]\]                                            Knee OA                Pain, other disease-specific symptoms, ADL function, sport and recreation, function, knee related QoL   5                 42             5                         P: 0--36 Sy: 0--28 A: 0--68 SP: 0--16 Q: 0--16   10                         Self-administered                 Many languages          No

  WOMAC \[[@B54-jcm-09-02439],[@B59-jcm-09-02439],[@B60-jcm-09-02439],[@B61-jcm-09-02439],[@B62-jcm-09-02439],[@B63-jcm-09-02439]\]                       Knee OA                Pain, physical function, stiffness                                                                      3                 24             5                         P: 0--20 S: 0--8 PF: 0--68                       5-10                       Self-administered                 Many languages          No

  KSS \[[@B64-jcm-09-02439],[@B65-jcm-09-02439]\]                                                                                                         Knee OA                Pain, expectation, satisfaction, physical function                                                      4                 34             Varies                    O: 0--100 Sa: 0--40 Ex: 0--15 F: 0--100          15                         Interview based and examination   English\                Yes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                  French\                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                  German\                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Chinese Portuguese\     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Dutch\                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Turkish                 

  OKS \[[@B66-jcm-09-02439],[@B67-jcm-09-02439],[@B68-jcm-09-02439],[@B69-jcm-09-02439]\]                                                                 Knee OA                Pain and physical function                                                                              1                 12             5                         12--60                                           10                         Self-administered                 Many languages          Yes

  HSS \[[@B70-jcm-09-02439],[@B71-jcm-09-02439]\]                                                                                                         TKA                    Expectation                                                                                             1                 19             5                         0-100                                            5-10                       Self-administered                 English\                No
                                                                                                                                                                                                                                                                                                                                                                                                                                                                  French                  

  **Patient-specific**                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  HDRS                                                                                                                                                    Depressed patients     Depression                                                                                              1                 17             Varies                    0--53                                            20--30                     Interview based                   Many languages          Yes

  STAI \[[@B72-jcm-09-02439]\]                                                                                                                            General population     Anxiety                                                                                                 2                 40             4                         S-A: 20--80 T-A: 20--80                          10                         Self-administered                 Many languages          Yes

  GDS \[[@B73-jcm-09-02439]\]                                                                                                                             Elderly                Depression                                                                                              1                 30             2                         0--30                                            5--10                      Self-administered                 Many languages          No

  HADS \[[@B72-jcm-09-02439],[@B73-jcm-09-02439],[@B74-jcm-09-02439],[@B75-jcm-09-02439],[@B76-jcm-09-02439]\]                                            General population     Anxiety and depression                                                                                  2                 14             4                         A: 0--21 D: 0--21                                5--10                      Self-administered                 Many languages          Yes

  **Generic**                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  SF-36 \[[@B23-jcm-09-02439],[@B24-jcm-09-02439],[@B61-jcm-09-02439],[@B62-jcm-09-02439],[@B77-jcm-09-02439],[@B78-jcm-09-02439],[@B79-jcm-09-02439]\]   General population     Pain, physical/mental/social function, general health                                                   8                 36             Varies                    0--100 PCS: 0--100 MCS: 0--100                   10                         Self-administered                 Many languages          No

  SF-12 \[[@B24-jcm-09-02439],[@B62-jcm-09-02439],[@B78-jcm-09-02439],[@B80-jcm-09-02439],[@B81-jcm-09-02439]\]                                           General population     Pain, physical/mental/social function, general health                                                   2                 12             Varies                    0--100 PCS: 0--100 MCS: 0--100                   5                          Self-administered                 Many languages          No

  PCS \[[@B82-jcm-09-02439]\]                                                                                                                             General population     Pain catastrophizing                                                                                    1                 13             5                         0--52 R: 0--16 M: 0--12 H: 0--24                 5                          Self-administered                 English French          Yes

  NRS pain \[[@B83-jcm-09-02439]\]                                                                                                                        General population     Pain severity                                                                                           1                 1              11                        0--10                                            1                          Self-administered                 No translation needed   No
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OA = osteoarthritis; TKA = total knee arthroplasty; ADL = activities of daily living; QoL = quality of life; P = pain subscale; Sy = symptoms subscale; A = activity limitations of daily living; SP = activity limitations for sport and recreation; Q = quality of life (knee related); S = stiffness subscale; PF = physical function subscale; O = objective subscale; Sa = satisfaction subscale; Ex = expectation subscale; F = functional activity subscale; S--A: the state anxiety scale; T--A: the trait anxiety scale; A: anxiety; D: depression; PCS = physical component summary; MCS = mental component summary; R = rumination; M = magnification; H = helplessness; see [Table 2](#jcm-09-02439-t002){ref-type="table"} for additional abbreviations. \# Population for which the questionnaire has been developed; ˥ Domains: domain(s) explored by the tool; **˩** Scales: a subscore within a tool; ǂ non-exhaustive list, see [Table A3](#jcm-09-02439-t0A3){ref-type="table"} for more details.
